|Bid||119.20 x 0|
|Ask||121.40 x 0|
|Day's Range||117.60 - 125.00|
|52 Week Range||105.00 - 197.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 16, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||240.67|
Subscribe to Yahoo Finance Plus to view Fair Value for SYNC.L
Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise.
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial proposal on October 18, in an all-cash transaction Based on extensive evaluation of available strategic and financing options, Freeline’s independent directors unanimously recommend transaction as best value for shareholders Syncona to provide $15 million in convertible debt financing to cover Freeline’s near-term capital needs and support ongoing adva
The planned acquisition adds to a string of bargain buyouts and reverse mergers in the gene therapy field.